CareDx, Inc. (CDNA)
Levi & Korsinsky, LLP announces that a CDNA class action lawsuit has been filed on behalf of investors who purchased CareDx, Inc. (CDNA) common stock between February 24, 2021, and May 5, 2022, inclusive. For more on the CDNA Lawsuit please contact us today.
According to the CareDx, Inc. lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:
(1) defendants had engaged in a variety of improper and illegal schemes to inflate testing services revenue and demand, including pushing a surveillance protocol through inaccurate marketing materials, offering extravagant inducements or kickbacks to physicians and other providers, and improperly bundling expensive testing services with other blood tests as part of the Company’s RemoTraC service for remote, home-based, blood-drawing; (2) these practices, and others, subjected CDNA to an undisclosed risk of regulatory scrutiny; (3) these practices rendered the Company’s testing services revenue reported throughout the class period artificially inflated; and (4) as a result, defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in CareDx, Inc. you have until July 22, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
CareDx, Inc. Class Action Lawsuit
CareDx, Inc. Lawsuit
CDNA Class Action Lawsuit
CareDx, Inc. (CDNA) Class Action Lawsuit